Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study

What Was Tested

This clinical trial, phase ii paper looks at Leuprolide.

Who Took Part

According to the abstract, 2 patients were involved.

PubMed indexes the participants as middle-aged adults, older adults and people over 80, men only.

This multi-institutional, single-arm, phase 2 trial enrolled patients with VHR localized prostate cancer, defined according to the National Comprehensive Cancer Network as histologically confirmed adenocarcinoma with ≥2 high-risk features: Gleason score 8 to 10, prostate-specific antigen (PSA) ≥20, clinical or radiographic ≥T3, or >4 cores containing Gleason score 8 disease.

Patients received 6 months of apalutamide, abiraterone acetate, and leuprolide plus prostate/seminal vesicle-directed ultra-fractionated SBRT.

How the Study Was Run

Secondary endpoints included PSA ≥0.2 ng/mL, metastasis-free survival (MFS), and time to testosterone recovery >150 ng/dL.

What Was Measured

The subject headings attached to it are Prostatic Neoplasms, Prednisone, Antineoplastic Combined Chemotherapy Protocols, Leuprolide, Abiraterone Acetate, Thiohydantoins and Radiosurgery.

What This Means in Plain Language

This is a clinical trial, phase ii of Leuprolide in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Clinical cancer research : an official journal of the American Association for Cancer Research), a journal based in United States.

More context: the Leuprolide compound page, all human trials.